Astellas Pharma Ltd., a leading global pharmaceutical company headquartered in the United Kingdom, is renowned for its innovative approach to healthcare. Founded in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas has established a strong presence in key operational regions, including Europe, North America, and Asia. Specialising in areas such as urology, oncology, and immunology, Astellas is committed to developing unique therapies that address unmet medical needs. The company’s core products, including the prostate cancer treatment Xtandi and the antifungal agent Cresemba, exemplify its dedication to advancing patient care. With a robust pipeline and a focus on research and development, Astellas Pharma Ltd. continues to solidify its position as a prominent player in the global pharmaceutical industry, recognised for its contributions to innovative healthcare solutions.
We don't have data for Astellas Pharma Ltd., but we can show you information about their parent organization instead.
View parent company